The Role of Exercise Testing in the Management of Pulmonary Arterial Hypertension

ABSTRACT

The assessment of exercise capacity is of critical importance in the evaluation and management of patients with moderate to severe pulmonary arterial hypertension (PAH). The practicing clinician uses various exercise modalities in evaluating and managing patients with PAH. These include the 6-minute walk test (6MW), cardiopulmonary exercise testing, and exercise echocardiography. The change in exercise capacity appears to parallel other clinical indicators of disease severity, such as survival, hemodynamics, and time to clinical worsening. Exercise testing can aid the clinician in outlining the nature of a patient's exercise limitation, noninvasively assessing disease severity, establishing prognosis, and evaluating the response to therapy. Additional work must be done to validate the utility of measuring exercise capacity in patients with less severe PAH.

KEYWORDS

Exercise testing - 6-minute walk test - cardiopulmonary exercise test

REFERENCES

• 1 Barst R J, Rubin L J, Long W A et al.. A comparison of continuous intravenous epoprostenol (prostacyclin) with conventional therapy for primary pulmonary hypertension. The Primary Pulmonary Hypertension Study Group.  N Engl J Med. 1996;  334 296-302
• 2 Rubin L J, Badesch D B, Barst R J et al.. Bosentan therapy for pulmonary arterial hypertension.  N Engl J Med. 2002;  346 896-903
• 3 Yetman A T, Taylor A L, Doran A, Ivy D D. Utility of cardiopulmonary stress testing in assessing disease severity in children with pulmonary arterial hypertension.  Am J Cardiol. 2005;  95 697-699
• 4 Wax D, Garofano R, Barst R J. Effects of long-term infusion of prostacyclin on exercise performance in patients with primary pulmonary hypertension.  Chest. 1999;  116 914-920
• 5 Guyatt G H, Sullivan M J, Thompson P J et al.. The 6-minute walk: a new measure of exercise capacity in patients with chronic heart failure.  Can Med Assoc J. 1985;  132 919-923
• 6 Channick R N, Simonneau G, Sitbon O et al.. Effects of the dual endothelin-receptor antagonist bosentan in patients with pulmonary hypertension: a randomised placebo-controlled study.  Lancet. 2001;  358 1119-1123
• 7 Galiè N, Humbert M, Vachiery J L et al.. Effects of beraprost sodium, an oral prostacyclin analogue, in patients with pulmonary arterial hypertension: a randomized, double-blind, placebo-controlled trial.  J Am Coll Cardiol. 2002;  39 1496-1502
• 8 Langleben D, Christman B W, Barst R J et al.. Effects of the thromboxane synthetase inhibitor and receptor antagonist terbogrel in patients with primary pulmonary hypertension.  Am Heart J. 2002;  143 E4
• 9 Olschewski H, Simonneau G, Galiè N et al.. Inhaled iloprost for severe pulmonary hypertension.  N Engl J Med. 2002;  347 322-329
• 10 Simonneau G, Barst R J, Galiè N et al.. Continuous subcutaneous infusion of treprostinil, a prostacyclin analogue, in patients with pulmonary arterial hypertension: a double-blind, randomized, placebo-controlled trial.  Am J Respir Crit Care Med. 2002;  165 800-804
• 11 Barst R J, McGoon M, McLaughlin V et al.. Beraprost therapy for pulmonary arterial hypertension.  J Am Coll Cardiol. 2003;  41 2119-2125
• 12 Borg G A. Psychophysical bases of perceived exertion.  Med Sci Sports Exerc. 1982;  14 377-381
• 13 Mahler D A, Weinberg D H, Wells C K, Feinstein A R. The measurement of dyspnea: contents, interobserver agreement, and physiologic correlates of two new clinical indexes.  Chest. 1984;  85 751-758
• 14 Sitbon O, Humbert M, Nunes H et al.. Long-term intravenous epoprostenol infusion in primary pulmonary hypertension: prognostic factors and survival.  J Am Coll Cardiol. 2002;  40 780-788
• 15 Miyamoto S, Nagaya N, Satoh T et al.. Clinical correlates and prognostic significance of six-minute walk test in patients with primary pulmonary hypertension: comparison with cardiopulmonary exercise testing.  Am J Respir Crit Care Med. 2000;  161 487-492
• 16 Paciocco G, Martinez F J, Bossone E, Pielsticker E, Gillespie B, Rubenfire M. Oxygen desaturation on the six-minute walk test and mortality in untreated primary pulmonary hypertension.  Eur Respir J. 2001;  17 647-652
• 17 Paciocco G, Martinez F J, Bossone E et al.. Oxygen desaturation on the six-minute walk test and mortality in untreated primary pulmonary hypertension.  Eur Respir J. 2001;  17 647-652
• 18 McGoon M, Gutterman D, Steen V et al.. Screening, early detection, and diagnosis of pulmonary arterial hypertension: ACCP evidence-based clinical practice guidelines.  Chest. 2004;  126(suppl) 14S-34S
• 19 Oudiz R J, Sun X G. Abnormalities in exercise gas exchange in primary pulmonary hypertension. In: Wasserman K Cardiopulmonary Exercise Testing and Cardiovascular Health Armonk, NY; Futura 2002: 179-190
• 20 Beaver W L, Wasserman K, Whipp B J. A new method for detecting anaerobic threshold by gas exchange.  J Appl Physiol. 1986;  60 2020-2027
• 21 Sun X-G, Oudiz R J, Hansen J E, Wasserman K. Exercise pathophysiology in primary pulmonary hypertension.  Circulation. 2001;  104 429-435
• 22 Wasserman K, Hansen JE, Sue DY, Casaburi R, Whipp BJ Principles of Exercise Testing and Interpretation. 4th ed. Philadelphia; Lippincott Williams & Wilkins 2004
• 23 Markowitz D H, Systrom D M. Diagnosis of pulmonary vascular limit to exercise by cardiopulmonary exercise testing.  J Heart Lung Transplant. 2004;  23 88-95
• 24 Deboeck G, Niset G, Lamotte M, Vachiery J-L, Naeije R. Exercise testing in pulmonary arterial hypertension and in chronic heart failure.  Eur Respir J. 2004;  23 747-751
• 25 Wensel R, Opitz C F, Anker S D et al.. Assessment of survival in patients with primary pulmonary hypertension: importance of cardiopulmonary exercise testing.  Circulation. 2002;  106 319-324
• 26 Janicki J S, Gupta S, Ferris S T et al.. Long-term reproducibility of respiratory gas exchange measurements during exercise in patients with stable cardiac failure.  Chest. 1990;  97 12-17
• 27 Hansen J E, Sun X G, Yasunobu Y et al.. Reproducibility of cardiopulmonary exercise measurements in patients with pulmonary arterial hypertension.  Chest. 2004;  126 816-824
• 28 Porszasz J, Casaburi R, Somfay A, Woodhouse L J, Whipp B J. A treadmill ramp protocol using simultaneous changes in speed and grade.  Med Sci Sports Exerc. 2003;  35 1596-1603
• 29 Himelman R B, Stulbarg M, Kircher B et al.. Noninvasive evaluation of pulmonary artery pressure during exercise by saline-enhanced Doppler echocardiography in chronic pulmonary disease.  Circulation. 1989;  79 863-871
• 30 Oelberg D A, Marcotte F, Kreisman H, Wolkove N, Langleben D, Small D. Evaluation of right ventricular systolic pressure during incremental exercise by Doppler echocardiography in adults with atrial septal defect.  Chest. 1998;  113 1459-1465
• 31 Vachiery J L, Brimioulle S, Crasset V, Naeije R. False-positive diagnosis of pulmonary hypertension by Doppler echocardiography.  Eur Respir J. 1998;  12 1476-1478
• 32 Sastry B K, Narasimhan C, Reddy N K, Raju B S. Clinical efficacy of sildenafil in primary pulmonary hypertension: a randomized, placebo-controlled, double-blind, crossover study.  J Am Coll Cardiol. 2004;  43 1149-1153
• 33 Yasunobu Y, Oudiz R J, Sun X, Hansen J, Wasserman K. End-tidal PCO₂ as a measure of ventilatory efficiency and exercise limitation in patients with primary pulmonary hypertension.  Chest. 2005;  127 1637-1646
• 34 Costanzo M R, Augustine S, Bourge R et al.. Selection and treatment of candidates for heart transplantation: a statement for health professionals from the Committee on Heart Failure and Cardiac Transplantation of the Council on Clinical Cardiology, American Heart Association.  Circulation. 1995;  92 3593-3612
• 35 Stevenson L W. Role of exercise testing in the evaluation of candidates for cardiac transplantation. In: Wasserman K Exercise Gas Exchange in Heart Disease Armonk, NY; Futura 1996: 271